Can a cannabis company claim the federal R&D tax credit?

Plant-touching businesses generally cannot. Section 280E disallows any deduction or credit for amounts paid or incurred in carrying on a trade or business that consists of trafficking in Schedule I or II controlled substances, and state-legal cannabis sales are trafficking for this purpose. Because Section 280E denies credits as well as deductions, the Section 41 research credit is unavailable for the trafficking trade or business, regardless of how qualified the research is.

Which cannabis-adjacent companies can still claim the R&D credit?

Businesses that never touch the plant — cultivation-technology, lighting, and equipment makers, seed-to-sale and compliance software developers, testing-device manufacturers, and hemp companies operating under the 2018 Farm Bill's 0.3% THC threshold — are not trafficking in a controlled substance and claim Section 41 on ordinary terms. A genuinely separate non-trafficking trade or business within a cannabis group can also claim, but only if it is truly separate on the Californians Helping to Alleviate Medical Problems framework.

Would rescheduling cannabis to Schedule III end the Section 280E problem?

Prospectively, yes. Section 280E applies only to Schedule I and II substances, so if cannabis were rescheduled to Schedule III, Section 280E would cease to apply to state-legal cannabis businesses from the effective date, opening ordinary deductions and credits including Section 41. It would not retroactively cure earlier years, and as of mid-2026 cannabis remains Schedule I; claims premised on anticipated rescheduling are premature.

Cannabis and the research credit: why Section 280E blocks most claims

Cannabis operators run real research — cultivar development, extraction chemistry, formulation science — and none of it earns a federal research credit if the business touches the plant. Section 280E disallows "any deduction or credit" for amounts paid or incurred in a trade or business that "consists of trafficking in controlled substances" within Schedule I or II of the Controlled Substances Act, and marijuana remains Schedule I as of mid-2026. The provision's text reaches credits by name, so the Section 41 credit falls with everything else. The planning questions are all at the edges: who counts as trafficking, what a separate trade or business can salvage, and what the states allow that the federal code does not.

The trafficking scope, and why credits cannot be rescued

Two features of Section 280E make it categorical. First, the courts read "trafficking" broadly: state-legal dispensing is trafficking (Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, 128 T.C. 173 (2007), the CHAMP case), and cultivation and manufacturing sit inside the same trafficking trade or business. Second, the only relief valve is constitutional, not statutory: cost of goods sold is an adjustment to gross receipts rather than a deduction, so producers recover inventoriable costs under Section 471 — but a credit has no COGS analogue. There is no capitalization strategy that converts a Section 41 credit into something 280E does not reach. Research wages a cultivator capitalizes into inventory reduce gross income through COGS; they still generate no credit, because the credit itself is what the statute denies. The Code's text is at uscode.house.gov.

Note the interaction most practitioners miss: the qualification analysis never gets started. Whether cultivar trials satisfy the four-part test, or extraction development produces valid QREs, is academic for the trafficking business — 280E operates downstream of Section 41 and switches the credit off at the return level.

Who can still claim

The dividing line is trafficking, not the word "cannabis" on the pitch deck:

Business	280E exposure	Section 41 availability
Cultivator, processor, dispensary (plant-touching)	Full	No federal credit
Hemp/CBD operator (≤0.3% delta-9 THC, 2018 Farm Bill)	None — not a controlled substance	Ordinary claim
Grow-tech, lighting, equipment manufacturer	None	Ordinary claim
Seed-to-sale, POS, compliance software developer	None	Ordinary claim
Testing-instrument maker; third-party analytical labs	Generally none	Ordinary claim
Non-trafficking line inside a plant-touching entity	Depends on separateness	Only if a genuinely separate trade or business

The last row is the contested one. CHAMP allowed a caregiving business conducted alongside dispensing to deduct its own expenses as a separate trade or business, while Olive v. Commissioner (9th Cir. 2015) refused to find separateness where the ancillary activity was intertwined with dispensing. A cannabis group wanting research credits for, say, its licensing-out technology arm needs real separation — distinct entity, books, employees, economics — and should expect the IRS to test it. Entity structuring here is exactly the kind of position that belongs in a memo before it appears on Form 6765.

State divergence

Section 280E's damage is federal; the states choose their own conformity. A number of adult-use states have decoupled from 280E for state income or franchise tax purposes, allowing cannabis businesses ordinary deductions — and, where the state offers its own research credit computed on a decoupled base, potentially a state R&D credit even while the federal credit is barred. Other states conform to the Code as written and import the disallowance. The pattern changes session by session; verify the current-year conformity statute and the state credit's own eligibility terms with the state revenue agency before claiming, and treat any state credit as a standalone analysis rather than a federal derivative.

The strategic summary is unusually clean for tax law: as of mid-2026, plant-touching means no federal Section 41 credit, full stop; ancillary and hemp businesses claim normally; separate-trade-or-business structures can work but are audit bait; and the entire analysis flips prospectively if cannabis leaves Schedules I and II. The IRS research credit overview governs everyone the day that happens.